| Host: |
HEK293 cells |
| Reactivity: |
SARS-CoV-2 |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-SARS-CoV-2 Spike S1-C-hFc protein was developed from hek293 cells and has a target region of C-hFc. For use in research applications. |
| Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4 or Supplied as a 0.22 Mu m filtered solution in PBS, pH 7.4. Contact us for customized product form or formulation. |
| Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human ACE2 Protein at 2 Mu g/mL (100 Mu L/well) can bind Recombinant SARS-CoV-2 Spike S1 Protein, the EC50 of Recombinant SARS-CoV-2 Spike S1 Protein is 47.35 ng/mL. |
| Immunogen Region: |
Val16-Arg685 |
| Immunogen: |
Recombinant SARS-CoV-2 Spike S1 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Val16-Arg685) of sars-cov-2 Spike S1 (Accession #YP_009724390.1) fused with a Fc tag at the C-terminus. |
| Background | Recombinant SARS-CoV-2 Spike S1 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Val16-Arg685) of sars-cov-2 Spike S1 (Accession #YP_009724390.1) fused with a Fc tag at the C-terminus. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
